ReviewNaunyn-Schmiedeberg's archives of pharmacology2010
Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- The role of ubiquitination in the pathogenesis of atrial fibrillation: mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Antiarrhythmic effects of metformin.Heart rhythm O2 · 2024Review
- Article
- Article
- The RyR2-P2328S mutation downregulates Nav1.5 producing arrhythmic substrate in murine ventricles.Pflugers Archiv : European journal of physiology · 2016Article
- The multi-biomarker approach for heart failure in patients with hypertension.International journal of molecular sciences · 2015Article
- Atrial fibrillation complicated by heart failure induces distinct remodeling of calcium cycling proteins.PloS one · 2015Article
- Abnormal Ca(2+) homeostasis, atrial arrhythmogenesis, and sinus node dysfunction in murine hearts modeling RyR2 modification.Frontiers in physiology · 2013Article
- Calcium handling and atrial fibrillation.Wiener medizinische Wochenschrift (1946) · 2012Review
- Ablation of sarcolipin results in atrial remodeling.American journal of physiology. Cell physiology · 2012Article
- Novel molecular targets for atrial fibrillation therapy.Nature reviews. Drug discovery · 2012Review
- Persistence of pro-arrhythmic spatio-temporal calcium patterns in atrial myocytes: a computational study of ping waves.Frontiers in physiology · 2012Article
- Decreased sarcolipin protein expression and enhanced sarco(endo)plasmic reticulum Ca2+ uptake in human atrial fibrillation.Biochemical and biophysical research communications · 2011Article
- Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2011Article
- Acute atrial arrhythmogenicity and altered Ca(2+) homeostasis in murine RyR2-P2328S hearts.Cardiovascular research · 2011Article
- The ryanodine receptor channel as a molecular motif in atrial fibrillation: pathophysiological and therapeutic implications.Cardiovascular research · 2011Review
- The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation.Vascular health and risk management · 2011Review
- Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits.Naunyn-Schmiedeberg's archives of pharmacology · 2010Article
- Role of abnormal sarcoplasmic reticulum function in atrial fibrillation.Therapy (London, England : 2004) · 2010Article
- Novel pharmacological approaches for antiarrhythmic therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most frequent arrhythmia and is associated with increased morbidity and mortality. Current drugs for AF treatment have moderate efficacy and increase the risk of life-threatening antiarrhythmias, making novel drug development crucial. Newer antiarrhythmic drugs like dronedarone and possibly vernakalant are efficient and may have less proarrhythmic potential. Emerging evidence suggests that abnormal intracellular Ca(2+) signaling is the key contributor to focal firing, substrate evolution, and atrial remodeling during AF. Accordingly, identification of the underlying atrial Ca(2+)-handling abnormalities is expected to discover novel mechanistically based therapeutic targets. This article reviews the molecular mechanisms of altered Ca(2+) signaling in AF and discusses the potential value of novel approaches targeting atrial Ca(2+)-handling abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.